Genmab A/S (NASDAQ:GMAB) and BioNTech SE (NASDAQ:BNTX) todayannounced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also

BNTX

News

micromobility.com Inc. Announces Strategic Realignment To Strengthen Its Financial Position And Drive Profitability

By Happy Mohamed

June 29, 8:13 AM

Exits Streaming Business to Focus on Core Competencies Directing Resources to Mobility to Revolutionize Transportation with Sustainable and Smart Solutions Strengthens Position in Mobility to Navigate towards

MCOM

Tentative U.S. Rail Deal Goes Back to Unions for a Vote; Parties Agree to Cooling Off Period as Part of Deal n Case Vote Fails in Order to Avert Any Shutdown

By Charles Gross

September 15, 6:14 AM

-Reuters Citing Source

Boeing Delivers Four Mh-139A Test Helicopters To U.S. Air Force

Related Posts

Chegg Q3 Earnings: Revenue Beat, EPS Beat, Subscribers Down 8%, Company Rolls Out AI-Powered Experience

Genmab, BioNTech Announced Data At ASCO, Showing Investigational Acasunlimab In Combination With Pembrolizumab Resulted In 12-month Overall Survival Rate of 69% In Patients With Previously Treated Metastatic Non-small Cell Lung Cancer

micromobility.com Inc. Announces Strategic Realignment To Strengthen Its Financial Position And Drive Profitability

Tentative U.S. Rail Deal Goes Back to Unions for a Vote; Parties Agree to Cooling Off Period as Part of Deal n Case Vote Fails in Order to Avert Any Shutdown